Neoadjuvant docetaxel and capecitabine (tx) versus docetaxel and epirubicin (te) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase ii trial

HIGHLIGHTS

• who: Houpu Yang from the Peking University People`s Hospital Breast Center, Beijing, China have published the research work: Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial, in the Journal: (JOURNAL) of December/31,/2018
• what: The combination of taxanes and anthracyclines is still the mainstay of chemotherapy for early is an active drug with a favorable toxicity profile showing strong anti-tumor activity against metastatic This trial assessed the efficacy and safety of the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.